323 related articles for article (PubMed ID: 30684677)
41. Are dementia with Lewy bodies and Parkinson's disease dementia the same disease?
Jellinger KA; Korczyn AD
BMC Med; 2018 Mar; 16(1):34. PubMed ID: 29510692
[TBL] [Abstract][Full Text] [Related]
42. Degeneration of nigrostriatal dopaminergic neurons in the early to intermediate stage of dementia with Lewy bodies and Parkinson's disease.
Okitsu M; Sugaya K; Nakata Y; Kawazoe T; Ikezawa J; Okiyama R; Takahashi K
J Neurol Sci; 2023 Jun; 449():120660. PubMed ID: 37084522
[TBL] [Abstract][Full Text] [Related]
43. Aggresome-related biogenesis of Lewy bodies.
McNaught KS; Shashidharan P; Perl DP; Jenner P; Olanow CW
Eur J Neurosci; 2002 Dec; 16(11):2136-48. PubMed ID: 12473081
[TBL] [Abstract][Full Text] [Related]
44. Dementia with Lewy bodies and Parkinson's disease-dementia: current concepts and controversies.
Jellinger KA
J Neural Transm (Vienna); 2018 Apr; 125(4):615-650. PubMed ID: 29222591
[TBL] [Abstract][Full Text] [Related]
45. Dementia with Lewy bodies: reclassification of pathological subtypes and boundary with Parkinson's disease or Alzheimer's disease.
Iseki E
Neuropathology; 2004 Mar; 24(1):72-8. PubMed ID: 15068176
[TBL] [Abstract][Full Text] [Related]
46. Hippocampal Lewy pathology and cholinergic dysfunction are associated with dementia in Parkinson's disease.
Hall H; Reyes S; Landeck N; Bye C; Leanza G; Double K; Thompson L; Halliday G; Kirik D
Brain; 2014 Sep; 137(Pt 9):2493-508. PubMed ID: 25062696
[TBL] [Abstract][Full Text] [Related]
47. Evidence that incidental Lewy body disease is pre-symptomatic Parkinson's disease.
Dickson DW; Fujishiro H; DelleDonne A; Menke J; Ahmed Z; Klos KJ; Josephs KA; Frigerio R; Burnett M; Parisi JE; Ahlskog JE
Acta Neuropathol; 2008 Apr; 115(4):437-44. PubMed ID: 18264713
[TBL] [Abstract][Full Text] [Related]
48. Nigral and cortical Lewy bodies and dystrophic nigral neurites in Parkinson's disease and cortical Lewy body disease contain alpha-synuclein immunoreactivity.
Irizarry MC; Growdon W; Gomez-Isla T; Newell K; George JM; Clayton DF; Hyman BT
J Neuropathol Exp Neurol; 1998 Apr; 57(4):334-7. PubMed ID: 9600226
[TBL] [Abstract][Full Text] [Related]
49. Activated microglial cells and complement factors are unrelated to cortical Lewy bodies.
Rozemuller AJ; Eikelenboom P; Theeuwes JW; Jansen Steur EN; de Vos RA
Acta Neuropathol; 2000 Dec; 100(6):701-8. PubMed ID: 11078223
[TBL] [Abstract][Full Text] [Related]
50. Repulsive Guidance Molecule a (RGMa) Induces Neuropathological and Behavioral Changes That Closely Resemble Parkinson's Disease.
Korecka JA; Moloney EB; Eggers R; Hobo B; Scheffer S; Ras-Verloop N; Pasterkamp RJ; Swaab DF; Smit AB; van Kesteren RE; Bossers K; Verhaagen J
J Neurosci; 2017 Sep; 37(39):9361-9379. PubMed ID: 28842419
[TBL] [Abstract][Full Text] [Related]
51. A neuropathological study of the disturbance of the nigro-amygdaloid connections in brains from patients with dementia with Lewy bodies.
Iseki E; Kato M; Marui W; Uéda K; Kosaka K
J Neurol Sci; 2001 Apr; 185(2):129-34. PubMed ID: 11311294
[TBL] [Abstract][Full Text] [Related]
52. TorsinA accumulation in Lewy bodies in sporadic Parkinson's disease.
Shashidharan P; Good PF; Hsu A; Perl DP; Brin MF; Olanow CW
Brain Res; 2000 Sep; 877(2):379-81. PubMed ID: 10986355
[TBL] [Abstract][Full Text] [Related]
53. Incidental Lewy body disease and preclinical Parkinson disease.
DelleDonne A; Klos KJ; Fujishiro H; Ahmed Z; Parisi JE; Josephs KA; Frigerio R; Burnett M; Wszolek ZK; Uitti RJ; Ahlskog JE; Dickson DW
Arch Neurol; 2008 Aug; 65(8):1074-80. PubMed ID: 18695057
[TBL] [Abstract][Full Text] [Related]
54. Spatial transcriptomics reveals molecular dysfunction associated with cortical Lewy pathology.
Goralski TM; Meyerdirk L; Breton L; Brasseur L; Kurgat K; DeWeerd D; Turner L; Becker K; Adams M; Newhouse DJ; Henderson MX
Nat Commun; 2024 Mar; 15(1):2642. PubMed ID: 38531900
[TBL] [Abstract][Full Text] [Related]
55. In vivo microglia activation in very early dementia with Lewy bodies, comparison with Parkinson's disease.
Iannaccone S; Cerami C; Alessio M; Garibotto V; Panzacchi A; Olivieri S; Gelsomino G; Moresco RM; Perani D
Parkinsonism Relat Disord; 2013 Jan; 19(1):47-52. PubMed ID: 22841687
[TBL] [Abstract][Full Text] [Related]
56. Cellular models for Parkinson's disease.
Falkenburger BH; Saridaki T; Dinter E
J Neurochem; 2016 Oct; 139 Suppl 1():121-130. PubMed ID: 27091001
[TBL] [Abstract][Full Text] [Related]
57. Relationships between Lewy bodies and pale bodies in Parkinson's disease.
Dale GE; Probst A; Luthert P; Martin J; Anderton BH; Leigh PN
Acta Neuropathol; 1992; 83(5):525-9. PubMed ID: 1320323
[TBL] [Abstract][Full Text] [Related]
58. Low Levels of Prohibitin in Substantia Nigra Makes Dopaminergic Neurons Vulnerable in Parkinson's Disease.
Dutta D; Ali N; Banerjee E; Singh R; Naskar A; Paidi RK; Mohanakumar KP
Mol Neurobiol; 2018 Jan; 55(1):804-821. PubMed ID: 28062948
[TBL] [Abstract][Full Text] [Related]
59. Neuronal cell cycle reentry events in the aging brain are more prevalent in neurodegeneration and lead to cellular senescence.
Wu D; Sun JK; Chow KH
PLoS Biol; 2024 Apr; 22(4):e3002559. PubMed ID: 38652714
[TBL] [Abstract][Full Text] [Related]
60. [Lewy bodies in Parkinson's disease: histological, immunohistochemical, and interferometric examinations].
Voronkov DN; Salkov VN; Anufriev PL; Khudoerkov RM
Arkh Patol; 2018; 80(4):9-13. PubMed ID: 30059066
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
